Increased values of the circulating PDGFβ sustains the “withdrawal syndrome” after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cells, molecules, & diseases molecules, & diseases, 2015-10, Vol.55 (3), p.211-212
Hauptverfasser:	Galimberti, Sara, Fontanelli, Giulia, Barsotti, Sara, Ricci, Federica, Guerrini, Francesca, Baratè, Claudia
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Female Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Middle Aged Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Proto-Oncogene Proteins c-sis - metabolism Receptor, Platelet-Derived Growth Factor beta - blood Substance Withdrawal Syndrome - blood Substance Withdrawal Syndrome - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!